drugset / Trial / NCT05507827
Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
Phase 1
Active not recruiting
22 enrolled
Stanford University
American Society of Hematology · collabNational Marrow Donor Program · collab
NaSingle-groupOpen-labelTreatment
Summary
To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD or graft failure.
Timeline
- Start
- 2022-08-18
- Primary completion
- 2025-06-18
- Completion
- 2045-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/CD22-BBz | Cell therapy | — | Intravenous |
| Subject | Orca-T | Cell therapy | — | — |